DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 3,000 shares, a drop of 33.3% from the July 15th total of 4,500 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 26,400 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On DA32 Life Science Tech Acquisition

A number of large investors have recently modified their holdings of the company. Exos Asset Management LLC lifted its holdings in shares of DA32 Life Science Tech Acquisition by 4.6% in the 1st quarter. Exos Asset Management LLC now owns 76,951 shares of the company's stock worth $748,000 after purchasing an additional 3,402 shares in the last quarter. Spartan Fund Management Inc. purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $181,000. Ursa Fund Management LLC purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $243,000. Piper Sandler & CO. purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $244,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $486,000. 60.86% of the stock is currently owned by institutional investors.

DA32 Life Science Tech Acquisition Price Performance

Shares of DALS remained flat at $9.72 during trading hours on Friday. The company had a trading volume of 3,602 shares, compared to its average volume of 19,005. DA32 Life Science Tech Acquisition has a 12 month low of $9.58 and a 12 month high of $10.26. The stock's 50 day moving average is $9.70 and its 200-day moving average is $9.69.

About DA32 Life Science Tech Acquisition

DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.

Further Reading

• Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?
• Look at Honeywell for a Steady and Diversified Stock
• Why Invest in High-Yield Dividend Stocks?

Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.